{"protocolSection": {"identificationModule": {"nctId": "NCT01103349", "orgStudyIdInfo": {"id": "1268.16"}, "secondaryIdInfos": [{"id": "2009-014551-80", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "BI 671800 in Asthmatic Patients on Inhaled Corticosteroids", "officialTitle": "Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)"}, "statusModule": {"statusVerifiedDate": "2022-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-04-20", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2011-08-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-08-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-03-19", "studyFirstSubmitQcDate": "2010-04-13", "studyFirstPostDateStruct": {"date": "2010-04-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-04-07", "resultsFirstSubmitQcDate": "2022-05-27", "resultsFirstPostDateStruct": {"date": "2022-05-31", "type": "ACTUAL"}, "dispFirstSubmitDate": "2014-04-30", "dispFirstSubmitQcDate": "2014-04-30", "dispFirstPostDateStruct": {"date": "2014-05-16", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-05-27", "lastUpdatePostDateStruct": {"date": "2022-05-31", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This is a 6 week study to assess the effect of BI 671800 in patients with asthma. It is a double blind, parallel arm trial testing the safety and efficacy of BI 671800. The main objective is to assess the effect on lung function. The study will also provide data on the pharmacokinetics of BI 671800."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 243, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BI 671800", "type": "EXPERIMENTAL", "description": "Patients receive BI 671800 capsules twice daily", "interventionNames": ["Drug: BI 671800"]}, {"label": "Montelukast", "type": "ACTIVE_COMPARATOR", "description": "Patients receive Montelukast encapsulated tablets once daily", "interventionNames": ["Drug: Montelukast"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Patients receive placebo capsules and/or encapsulated placebo tablets", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "BI 671800", "description": "Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma", "armGroupLabels": ["BI 671800"]}, {"type": "DRUG", "name": "Placebo", "description": "Patients receive placebo capsules and/or encapsulated tablets", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Montelukast", "description": "Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma", "armGroupLabels": ["Montelukast"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment", "description": "Forced expiratory volume in one second (FEV1) % predicted trough change from baseline (mean observed in the 2 weeks prior to treatment) after 6 weeks of treatment, where trough FEV1 % predicted was defined as the mean of the FEV1 % predicted trough values at 25 minutes and 10 minutes prior to dosing on clinic visit.\n\nMMRM in the statistical test comments is Mixed effects model with repeated measures.", "timeFrame": "Measurements at baseline (mean observed in the 2 weeks prior to treatment) and at week 6 of treatment."}], "secondaryOutcomes": [{"measure": "Asthma Control Questionnaire (ACQ) Mean Change in Score on a Scale From Baseline After Six Weeks of Treatment", "description": "Asthma Control Questionnaire (ACQ) mean score change from baseline (mean ACQ score obtained at Week 0) after six weeks of treatment.\n\nThe Asthma Control Questionnaire (ACQ) is a patient-reported outcome questionnaire containing 7 items. The items are equally weighted and the ACQ score is the mean of the 7 items and therefore between 0 (well controlled) and 6 (extremely poorly controlled) These questions based on recall of the previous 7 days comprise breathlessness, nocturnal waking, symptoms on waking, activity limitation, wheeze, frequency of Short-acting beta-adrenergic (SABA) use, and categorized pre-bronchodilator FEV1% predicted.", "timeFrame": "Measurements at baseline (mean ACQ score obtained at Week 0) and at week 6 of treatment."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Signed informed consent consistent with ICH-GCP\n2. Three month history of reversible (12% and 200 mL in forced expiratory volume in one second - FEV1) asthma (according to GINA) with following spirometry at randomisation: FEV1 60%- 85%.\n3. Stable inhaled corticosteroids (iCS) dose 3 months prior to screening.\n4. Diagnosis of asthma prior to 40 years.\n5. Asthma Control Questionnaire (ACQ) at least 1.5 at randomisation.\n6. Male or female 18 to 65 years.\n7. Non-smokers or ex-smokers (less than 10 pack years history) with negative cotinine screen.\n8. Able to perform pulmonary function testing.\n\nExclusion criteria:\n\n1. Significant diseases other than asthma or allergic rhinitis.\n2. Hepatic transaminases or total bilirubin greater than 1.5 ULN.\n3. Hospitalisation for asthma exacerbation or asthma related intubation within 3 months.\n4. Uncontrolled asthma on iCS + other controller.\n5. Respiratory tract infection or exacerbation within 4 weeks.\n6. FEV1 less than 40%, more than 12 puffs rescue salbutamol on more than two consecutive days, or asthma exacerbation during run-in period.\n7. Participation in another interventional study.\n8. Pregnant or nursing women.\n9. Women of child bearing potential not using appropriate methods of birth control as defined by the study protocol.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1268.16.01004 Boehringer Ingelheim Investigational Site", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "1268.16.01001 Boehringer Ingelheim Investigational Site", "city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "1268.16.01006 Boehringer Ingelheim Investigational Site", "city": "Plymouth", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 45.01052, "lon": -93.45551}}, {"facility": "1268.16.01003 Boehringer Ingelheim Investigational Site", "city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "1268.16.01002 Boehringer Ingelheim Investigational Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "1268.16.01005 Boehringer Ingelheim Investigational Site", "city": "El Paso", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "1268.16.43002 Boehringer Ingelheim Investigational Site", "city": "Feldbach", "country": "Austria", "geoPoint": {"lat": 46.95306, "lon": 15.88833}}, {"facility": "1268.16.49018 Boehringer Ingelheim Investigational Site", "city": "Aschaffenburg", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "1268.16.49014 Boehringer Ingelheim Investigational Site", "city": "Bamberg", "country": "Germany", "geoPoint": {"lat": 49.89873, "lon": 10.90067}}, {"facility": "1268.16.49001 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1268.16.49004 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1268.16.49010 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1268.16.49012 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1268.16.49013 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1268.16.49016 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1268.16.49008 Boehringer Ingelheim Investigational Site", "city": "Erfurt", "country": "Germany", "geoPoint": {"lat": 50.9787, "lon": 11.03283}}, {"facility": "1268.16.49005 Boehringer Ingelheim Investigational Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "1268.16.49015 Boehringer Ingelheim Investigational Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "1268.16.49011 Boehringer Ingelheim Investigational Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "1268.16.49009 Boehringer Ingelheim Investigational Site", "city": "Hannover", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "1268.16.49017 Boehringer Ingelheim Investigational Site", "city": "Hannover", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "1268.16.49007 Boehringer Ingelheim Investigational Site", "city": "Koblenz", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "1268.16.49006 Boehringer Ingelheim Investigational Site", "city": "L\u00fcbeck", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "1268.16.49002 Boehringer Ingelheim Investigational Site", "city": "R\u00fcdersdorf", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "1268.16.49003 Boehringer Ingelheim Investigational Site", "city": "Weinheim", "country": "Germany", "geoPoint": {"lat": 49.54887, "lon": 8.66697}}, {"facility": "1268.16.39006 Boehringer Ingelheim Investigational Site", "city": "Ferrara", "country": "Italy", "geoPoint": {"lat": 44.83804, "lon": 11.62057}}, {"facility": "1268.16.39007 Boehringer Ingelheim Investigational Site", "city": "Milano", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "1268.16.39004 Boehringer Ingelheim Investigational Site", "city": "Pietra Ligure (SV)", "country": "Italy"}, {"facility": "1268.16.39001 Boehringer Ingelheim Investigational Site", "city": "Pisa", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "1268.16.82008 Boehringer Ingelheim Investigational Site", "city": "Anyang", "country": "Korea, Republic of", "geoPoint": {"lat": 37.3925, "lon": 126.92694}}, {"facility": "1268.16.82009 Boehringer Ingelheim Investigational Site", "city": "Bucheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "1268.16.82007 Boehringer Ingelheim Investigational Site", "city": "Cheongju", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "1268.16.82006 Boehringer Ingelheim Investigational Site", "city": "Daegu", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "1268.16.82010 Boehringer Ingelheim Investigational Site", "city": "Gwangju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "1268.16.82001 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1268.16.82002 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1268.16.82004 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1268.16.82005 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1268.16.82003 Boehringer Ingelheim Investigational Site", "city": "Suwon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "1268.16.64001 Boehringer Ingelheim Investigational Site", "city": "Christchurch NZ", "country": "New Zealand"}, {"facility": "1268.16.64003 Boehringer Ingelheim Investigational Site", "city": "Greenlane East Auckland", "country": "New Zealand"}, {"facility": "1268.16.46002 Boehringer Ingelheim Investigational Site", "city": "G\u00f6teborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "1268.16.46001 Boehringer Ingelheim Investigational Site", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "1268.16.46003 Boehringer Ingelheim Investigational Site", "city": "\u00d6rebro", "country": "Sweden", "geoPoint": {"lat": 59.27412, "lon": 15.2066}}, {"facility": "1268.16.90002 Boehringer Ingelheim Investigational Site", "city": "Bursa", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"facility": "1268.16.90003 Boehringer Ingelheim Investigational Site", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "1268.16.90004 Boehringer Ingelheim Investigational Site", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "1268.16.90006 Boehringer Ingelheim Investigational Site", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "1268.16.90001 Boehringer Ingelheim Investigational Site", "city": "Mersin", "country": "Turkey", "geoPoint": {"lat": 36.79526, "lon": 34.61792}}, {"facility": "1268.16.44005 Boehringer Ingelheim Investigational Site", "city": "Chertsey", "country": "United Kingdom", "geoPoint": {"lat": 51.38812, "lon": -0.50782}}, {"facility": "1268.16.44004 Boehringer Ingelheim Investigational Site", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "1268.16.44002 Boehringer Ingelheim Investigational Site", "city": "Manchester", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "1268.16.44003 Boehringer Ingelheim Investigational Site", "city": "Southampton", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Related Info", "url": "http://www.mystudywindow.com/"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct. Rescue medication was allowed for all subjects as required.", "recruitmentDetails": "This was a Phase IIa, multicentre, multinational, randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of oral BI 671800 ED 400 mg b.i.d., montelukast 10 mg q.d., or placebo in symptomatic asthma patients on Fluticasone propionate Hydrofluoralkane Metered Dose Inhaler (100\u03bcg b.i.d.).", "groups": [{"id": "FG000", "title": "Placebo", "description": "Daily treatment with 4 oral capsules of BI 671800 Ethylenediamine (ED) placebo in the morning and 4 oral capsules of BI 671800 ED placebo plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks."}, {"id": "FG001", "title": "BI 671800 400 mg Bid", "description": "Daily treatment with 4 oral capsules of 100 milligram (mg) BI 67800 Ethylenediamine (ED) in the morning and 4 oral capsules of 100 mg BI 67800 ED plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks."}, {"id": "FG002", "title": "Montelukast 10 mg qd", "description": "Daily treatment with 4 oral capsules of BI 67800 Ethylenediamine (ED) Placebo in the morning and 4 oral capsules of BI 67800 ED Placebo plus 1 table of 10 mg over-encapsulated montelukast in the evening, for a total treatment period of 6 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "95"}, {"groupId": "FG001", "numSubjects": "81"}, {"groupId": "FG002", "numSubjects": "67"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "84"}, {"groupId": "FG001", "numSubjects": "74"}, {"groupId": "FG002", "numSubjects": "63"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Consent withdrawn", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Incorrectly included in the trial", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "did not want to take trial medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "forgot to take medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated Set (TS): All randomized patients who received at least one dose of treatment, the treated set was used in the safety analysis.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Daily treatment with 4 oral capsules of BI 671800 Ethylenediamine (ED) placebo in the morning and 4 oral capsules of BI 671800 ED placebo plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks."}, {"id": "BG001", "title": "BI 671800 400 mg Bid", "description": "Daily treatment with 4 oral capsules of 100 milligram (mg) BI 67800 Ethylenediamine (ED) in the morning and 4 oral capsules of 100 mg BI 67800 ED plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks."}, {"id": "BG002", "title": "Montelukast 10 mg qd", "description": "Daily treatment with 4 oral capsules of BI 67800 Ethylenediamine (ED) Placebo in the morning and 4 oral capsules of BI 67800 ED Placebo plus 1 table of 10 mg over-encapsulated montelukast in the evening, for a total treatment period of 6 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "81"}, {"groupId": "BG002", "value": "67"}, {"groupId": "BG003", "value": "243"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41.4", "spread": "12.64"}, {"groupId": "BG001", "value": "41.8", "spread": "12.67"}, {"groupId": "BG002", "value": "41.7", "spread": "11.97"}, {"groupId": "BG003", "value": "41.6", "spread": "12.42"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "42"}, {"groupId": "BG003", "value": "147"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "25"}, {"groupId": "BG003", "value": "96"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "8"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "93"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "65"}, {"groupId": "BG003", "value": "235"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "29"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "4"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "66"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "199"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "11"}]}]}]}, {"title": "Percentage of predicted forced expiratory volume in one second (FEV1)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage of predicted FEV1", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "68.089", "spread": "10.9109"}, {"groupId": "BG001", "value": "69.286", "spread": "10.5542"}, {"groupId": "BG002", "value": "69.842", "spread": "10.5288"}, {"groupId": "BG003", "value": "68.986", "spread": "10.6644"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment", "description": "Forced expiratory volume in one second (FEV1) % predicted trough change from baseline (mean observed in the 2 weeks prior to treatment) after 6 weeks of treatment, where trough FEV1 % predicted was defined as the mean of the FEV1 % predicted trough values at 25 minutes and 10 minutes prior to dosing on clinic visit.\n\nMMRM in the statistical test comments is Mixed effects model with repeated measures.", "populationDescription": "Statistical analysis was performed on randomized patients who received at least one dose of treatment and had both baseline and the post-baseline measurement at 6 weeks for the primary efficacy variable.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "FEV1 percent predicted", "timeFrame": "Measurements at baseline (mean observed in the 2 weeks prior to treatment) and at week 6 of treatment.", "groups": [{"id": "OG000", "title": "Placebo", "description": "Daily treatment with 4 oral capsules of BI 671800 Ethylenediamine (ED) placebo in the morning and 4 oral capsules of BI 671800 ED placebo plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks."}, {"id": "OG001", "title": "BI 671800 400 mg Bid", "description": "Daily treatment with 4 oral capsules of 100 milligram (mg) BI 67800 Ethylenediamine (ED) in the morning and 4 oral capsules of 100 mg BI 67800 ED plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks."}, {"id": "OG002", "title": "Montelukast 10 mg qd", "description": "Daily treatment with 4 oral capsules of BI 67800 Ethylenediamine (ED) Placebo in the morning and 4 oral capsules of BI 67800 ED Placebo plus 1 table of 10 mg over-encapsulated montelukast in the evening, for a total treatment period of 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "74"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.859", "spread": "1.029"}, {"groupId": "OG001", "value": "3.011", "spread": "1.082"}, {"groupId": "OG002", "value": "1.510", "spread": "1.181"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: Mean FEV1 % predicted trough change from baseline (BI671800 ED 400 mg bid) \u2264 Mean FEV1 % predicted trough change from baseline (placebo)", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0050", "pValueComment": "\u03b1=0.025 one-sided", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "MMRM with baseline, treatment, day, treatment by day interaction and baseline by day interaction as fixed effects and patient as a random effect.", "paramType": "Adjusted mean treatment differences", "paramValue": "3.870", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.931", "ciUpperLimit": "6.809", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.494"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "H0: Mean FEV1 % predicted trough change from baseline (Montelukast 10 mg qd) \u2264 Mean FEV1 % predicted trough change from baseline (placebo)", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0657", "pValueComment": "\u03b1=0.025 one-sided", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "MMRM with baseline, treatment, day, treatment by day interaction and baseline by day interaction as fixed effects and patient as a random effect.", "paramType": "Adjusted mean treatment differences", "paramValue": "2.369", "ciPctValue": "95", "ciLowerLimit": "-0.713", "ciUpperLimit": "5.452", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.567"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "H0: Mean FEV1 % predicted trough change from baseline (BI671800 ED 400 mg bid) \u2264 Mean FEV1 % predicted trough change from baseline (Montelukast 10 mg qd)", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1748", "pValueComment": "\u03b1=0.025 one-sided", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "MMRM with baseline, treatment, day, treatment by day interaction and baseline by day interaction as fixed effects and patient as a random effect.", "paramType": "Adjusted mean treatment differences", "paramValue": "1.501", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.652", "ciUpperLimit": "4.653", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.602"}]}, {"type": "SECONDARY", "title": "Asthma Control Questionnaire (ACQ) Mean Change in Score on a Scale From Baseline After Six Weeks of Treatment", "description": "Asthma Control Questionnaire (ACQ) mean score change from baseline (mean ACQ score obtained at Week 0) after six weeks of treatment.\n\nThe Asthma Control Questionnaire (ACQ) is a patient-reported outcome questionnaire containing 7 items. The items are equally weighted and the ACQ score is the mean of the 7 items and therefore between 0 (well controlled) and 6 (extremely poorly controlled) These questions based on recall of the previous 7 days comprise breathlessness, nocturnal waking, symptoms on waking, activity limitation, wheeze, frequency of Short-acting beta-adrenergic (SABA) use, and categorized pre-bronchodilator FEV1% predicted.", "populationDescription": "Statistical analysis was performed on randomized patients who received at least one dose of treatment and had both baseline and the post-baseline measurement at 6 weeks for the primary efficacy variable.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Measurements at baseline (mean ACQ score obtained at Week 0) and at week 6 of treatment.", "groups": [{"id": "OG000", "title": "Placebo", "description": "Daily treatment with 4 oral capsules of BI 671800 Ethylenediamine (ED) placebo in the morning and 4 oral capsules of BI 671800 ED placebo plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks."}, {"id": "OG001", "title": "BI 671800 400 mg Bid", "description": "Daily treatment with 4 oral capsules of 100 milligram (mg) BI 67800 Ethylenediamine (ED) in the morning and 4 oral capsules of 100 mg BI 67800 ED plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks."}, {"id": "OG002", "title": "Montelukast 10 mg qd", "description": "Daily treatment with 4 oral capsules of BI 67800 Ethylenediamine (ED) Placebo in the morning and 4 oral capsules of BI 67800 ED Placebo plus 1 table of 10 mg over-encapsulated montelukast in the evening, for a total treatment period of 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "74"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.418", "spread": "0.081"}, {"groupId": "OG001", "value": "-0.698", "spread": "0.085"}, {"groupId": "OG002", "value": "-0.598", "spread": "0.093"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0092", "pValueComment": "\u03b1=0.025 one-sided", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "MMRM with baseline, treatment, day, treatment by day interaction and baseline by day interaction as fixed effects and patient as a random effect.", "paramType": "Adjusted mean treatment differences", "paramValue": "-0.280", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.512", "ciUpperLimit": "-0.048", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.118"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0732", "pValueComment": "\u03b1=0.025 one-sided", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "MMRM with baseline, treatment, day, treatment by day interaction and baseline by day interaction as fixed effects and patient as a random effect.", "paramType": "Adjusted mean treatment differences", "paramValue": "-0.180", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.423", "ciUpperLimit": "0.063", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.124"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.2139", "pValueComment": "\u03b1=0.025 one-sided", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "MMRM with baseline, treatment, day, treatment by day interaction and baseline by day interaction as fixed effects and patient as a random effect.", "paramType": "Adjusted mean treatment differences", "paramValue": "-0.100", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.347", "ciUpperLimit": "0.147", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.126"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse Events: Day of the first dose till the day of the last dose + 5 days residual effect period, up to 64 days. All-Cause Mortality: Day of the first dose till the day of the last dose + 2 weeks follow up, up to 73 days.", "description": "Treated Set (TS): All randomized patients who received at least one dose of treatment, the treated set was used in the safety analysis.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Daily treatment with 4 oral capsules of BI 671800 Ethylenediamine (ED) placebo in the morning and 4 oral capsules of BI 671800 ED placebo plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 95, "seriousNumAffected": 0, "seriousNumAtRisk": 95, "otherNumAffected": 18, "otherNumAtRisk": 95}, {"id": "EG001", "title": "BI 671800 400 mg Bid", "description": "Daily treatment with 4 oral capsules of 100 milligram (mg) BI 67800 Ethylenediamine (ED) in the morning and 4 oral capsules of 100 mg BI 67800 ED plus 1 over-encapsulated montelukast placebo tablet in the evening, for a total treatment period of 6 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 81, "seriousNumAffected": 1, "seriousNumAtRisk": 81, "otherNumAffected": 10, "otherNumAtRisk": 81}, {"id": "EG002", "title": "Montelukast 10 mg qd", "description": "Daily treatment with 4 oral capsules of BI 67800 Ethylenediamine (ED) Placebo in the morning and 4 oral capsules of BI 67800 ED Placebo plus 1 table of 10 mg over-encapsulated montelukast in the evening, for a total treatment period of 6 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 67, "seriousNumAffected": 0, "seriousNumAtRisk": 67, "otherNumAffected": 8, "otherNumAtRisk": 67}], "seriousEvents": [{"term": "Hepatitis toxic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 67}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 95}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 67}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 95}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 67}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 95}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 67}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim, Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "relevance": "LOW"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}